The panic attack treatment market size has grown rapidly in recent years. It will grow from $3.04 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 17.8%. The growth during the historic period can be attributed to a reduction in public stigma surrounding mental health conditions, an increase in awareness campaigns by health organizations, rising diagnosis rates of anxiety disorders in developed regions, the inclusion of mental health in primary healthcare settings, and the expansion of private mental health clinics.
The panic attack treatment market size is expected to see rapid growth in the next few years. It will grow to $6.86 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period is driven by the rising prevalence of anxiety and panic disorders across all age groups, greater adoption of telehealth and digital therapy apps, a stronger focus on personalized and precision psychiatry, increased investments in mental health startups and innovations, and enhanced public-private partnerships in mental health service delivery. Key trends in the forecast period include the mainstream adoption of virtual reality-based exposure therapy, a rise in mobile apps for delivering cognitive behavioral therapy, a shift toward holistic and integrative treatment approaches, growing use of wearable biosensors for real-time anxiety tracking, and the incorporation of mindfulness and meditation into clinical regimens.
The rising prevalence of anxiety is expected to drive the growth of the panic attack treatment market. Anxiety is a mental health condition marked by persistent feelings of worry, nervousness, and fear, often accompanied by physical symptoms such as restlessness, rapid heartbeat, and difficulty concentrating. The pressures of modern life contribute to increasing anxiety levels by demanding high productivity, financial stability, and social success, leaving little room for rest or emotional recovery. Panic attack treatments address anxiety by providing effective solutions to alleviate symptoms, improve emotional well-being, and help individuals regain control of their lives through personalized and timely interventions. For example, in May 2024, the American Psychiatric Association (APA) reported that a growing number of U.S. adults are feeling more anxious, with 43% of adults in 2024 experiencing higher anxiety levels compared to 37% in 2023 and 32% in 2022. As a result, the increasing prevalence of anxiety is driving the demand for panic attack treatments.
Leading companies in the panic attack treatment market are focusing on advancements in medical technology, such as digital anxiety relief platforms, to improve the management of anxiety and panic attacks with accessible, technology-driven solutions. These platforms are technology-based applications or services designed to help individuals manage and reduce anxiety using tools such as guided meditation, cognitive behavioral therapy (CBT) modules, mood tracking, and relaxation exercises. For instance, in October 2024, CalmiGo, a U.S.-based mental health startup, launched CalmiGo Plus, an advanced digital platform aimed at supporting users in managing anxiety and panic attacks more effectively. The platform includes a patented, sensor-based exhaler device and a companion mobile app that leverages gamification and personalized therapeutic techniques to improve mental health outcomes. This innovation offers users immediate, drug-free relief while also tracking their progress over time, marking a significant leap forward in accessible and data-driven anxiety treatment solutions.
In August 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for \$8.7 billion. With this acquisition, AbbVie aimed to strengthen its neuroscience portfolio by gaining access to Cerevel’s promising pipeline of treatments for psychiatric and neurological disorders, including anxiety and panic-related conditions. Cerevel Therapeutics, a U.S.-based clinical-stage biopharmaceutical company, focuses on developing therapies for neuroscience-related diseases, including panic attacks.
Major players in the panic attack treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Shionogi & Co. Ltd., Lundbeck A/S, Recordati Rare Diseases, and Torrent Pharmaceuticals Ltd.
North America was the largest region in the panic attack treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in panic attack treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the panic attack treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Panic attack treatment refers to a range of medical and psychological interventions designed to manage, reduce, and prevent sudden, intense episodes of fear or discomfort, marked by physical and emotional distress. These treatments aim to restore emotional stability, minimize disruptions to daily functioning, and support long-term mental well-being for individuals affected by panic-related disorders.
The main treatment types for panic attacks include cognitive behavioral therapy (CBT), medications, and others. Cognitive behavioral therapy (CBT) is a structured, time-limited psychotherapeutic approach used in treating panic attacks, helping individuals identify and alter negative thought patterns and behaviors that trigger or exacerbate anxiety symptoms. The drug classes used in these treatments include antidepressants, anti-anxiety medications, calcitonin gene-related peptide (CGRP) antagonists, and others. These medications are administered through various routes such as oral, intravenous, intramuscular, sublingual, and more, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are used in settings such as hospitals, mental healthcare centers, and others.
The panic attack treatment market research report is one of a series of new reports that provides panic attack treatment market statistics, including panic attack treatment industry global market size, regional shares, competitors with a panic attack treatment market share, detailed panic attack treatment market segments, market trends and opportunities, and any further data you may need to thrive in the panic attack treatment industry. This panic attack treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The panic attack treatment market consists of revenues earned by entities by providing services such as exposure therapy sessions, dialectical behavior therapy, telepsychiatry and remote consultation services, mental wellness subscription platforms, supportive counseling and peer group therapy, and personalized mental health coaching. The market value includes the value of related goods sold by the service provider or included within the service offering. The panic attack treatment market also includes sales of biofeedback and neurofeedback devices, virtual reality-based therapy solutions, mobile mental health applications, genetic testing kits for psychiatric profiling, mental health diagnostic and screening tools, wearable devices for anxiety monitoring, AI-powered therapeutic chatbots, and digital therapeutic platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The panic attack treatment market size is expected to see rapid growth in the next few years. It will grow to $6.86 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period is driven by the rising prevalence of anxiety and panic disorders across all age groups, greater adoption of telehealth and digital therapy apps, a stronger focus on personalized and precision psychiatry, increased investments in mental health startups and innovations, and enhanced public-private partnerships in mental health service delivery. Key trends in the forecast period include the mainstream adoption of virtual reality-based exposure therapy, a rise in mobile apps for delivering cognitive behavioral therapy, a shift toward holistic and integrative treatment approaches, growing use of wearable biosensors for real-time anxiety tracking, and the incorporation of mindfulness and meditation into clinical regimens.
The rising prevalence of anxiety is expected to drive the growth of the panic attack treatment market. Anxiety is a mental health condition marked by persistent feelings of worry, nervousness, and fear, often accompanied by physical symptoms such as restlessness, rapid heartbeat, and difficulty concentrating. The pressures of modern life contribute to increasing anxiety levels by demanding high productivity, financial stability, and social success, leaving little room for rest or emotional recovery. Panic attack treatments address anxiety by providing effective solutions to alleviate symptoms, improve emotional well-being, and help individuals regain control of their lives through personalized and timely interventions. For example, in May 2024, the American Psychiatric Association (APA) reported that a growing number of U.S. adults are feeling more anxious, with 43% of adults in 2024 experiencing higher anxiety levels compared to 37% in 2023 and 32% in 2022. As a result, the increasing prevalence of anxiety is driving the demand for panic attack treatments.
Leading companies in the panic attack treatment market are focusing on advancements in medical technology, such as digital anxiety relief platforms, to improve the management of anxiety and panic attacks with accessible, technology-driven solutions. These platforms are technology-based applications or services designed to help individuals manage and reduce anxiety using tools such as guided meditation, cognitive behavioral therapy (CBT) modules, mood tracking, and relaxation exercises. For instance, in October 2024, CalmiGo, a U.S.-based mental health startup, launched CalmiGo Plus, an advanced digital platform aimed at supporting users in managing anxiety and panic attacks more effectively. The platform includes a patented, sensor-based exhaler device and a companion mobile app that leverages gamification and personalized therapeutic techniques to improve mental health outcomes. This innovation offers users immediate, drug-free relief while also tracking their progress over time, marking a significant leap forward in accessible and data-driven anxiety treatment solutions.
In August 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for \$8.7 billion. With this acquisition, AbbVie aimed to strengthen its neuroscience portfolio by gaining access to Cerevel’s promising pipeline of treatments for psychiatric and neurological disorders, including anxiety and panic-related conditions. Cerevel Therapeutics, a U.S.-based clinical-stage biopharmaceutical company, focuses on developing therapies for neuroscience-related diseases, including panic attacks.
Major players in the panic attack treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Shionogi & Co. Ltd., Lundbeck A/S, Recordati Rare Diseases, and Torrent Pharmaceuticals Ltd.
North America was the largest region in the panic attack treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in panic attack treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the panic attack treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Panic attack treatment refers to a range of medical and psychological interventions designed to manage, reduce, and prevent sudden, intense episodes of fear or discomfort, marked by physical and emotional distress. These treatments aim to restore emotional stability, minimize disruptions to daily functioning, and support long-term mental well-being for individuals affected by panic-related disorders.
The main treatment types for panic attacks include cognitive behavioral therapy (CBT), medications, and others. Cognitive behavioral therapy (CBT) is a structured, time-limited psychotherapeutic approach used in treating panic attacks, helping individuals identify and alter negative thought patterns and behaviors that trigger or exacerbate anxiety symptoms. The drug classes used in these treatments include antidepressants, anti-anxiety medications, calcitonin gene-related peptide (CGRP) antagonists, and others. These medications are administered through various routes such as oral, intravenous, intramuscular, sublingual, and more, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are used in settings such as hospitals, mental healthcare centers, and others.
The panic attack treatment market research report is one of a series of new reports that provides panic attack treatment market statistics, including panic attack treatment industry global market size, regional shares, competitors with a panic attack treatment market share, detailed panic attack treatment market segments, market trends and opportunities, and any further data you may need to thrive in the panic attack treatment industry. This panic attack treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The panic attack treatment market consists of revenues earned by entities by providing services such as exposure therapy sessions, dialectical behavior therapy, telepsychiatry and remote consultation services, mental wellness subscription platforms, supportive counseling and peer group therapy, and personalized mental health coaching. The market value includes the value of related goods sold by the service provider or included within the service offering. The panic attack treatment market also includes sales of biofeedback and neurofeedback devices, virtual reality-based therapy solutions, mobile mental health applications, genetic testing kits for psychiatric profiling, mental health diagnostic and screening tools, wearable devices for anxiety monitoring, AI-powered therapeutic chatbots, and digital therapeutic platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Panic Attack Treatment Market Characteristics3. Panic Attack Treatment Market Trends And Strategies4. Panic Attack Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Panic Attack Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Panic Attack Treatment Market34. Recent Developments In The Panic Attack Treatment Market
5. Global Panic Attack Treatment Growth Analysis And Strategic Analysis Framework
6. Panic Attack Treatment Market Segmentation
7. Panic Attack Treatment Market Regional And Country Analysis
8. Asia-Pacific Panic Attack Treatment Market
9. China Panic Attack Treatment Market
10. India Panic Attack Treatment Market
11. Japan Panic Attack Treatment Market
12. Australia Panic Attack Treatment Market
13. Indonesia Panic Attack Treatment Market
14. South Korea Panic Attack Treatment Market
15. Western Europe Panic Attack Treatment Market
16. UK Panic Attack Treatment Market
17. Germany Panic Attack Treatment Market
18. France Panic Attack Treatment Market
19. Italy Panic Attack Treatment Market
20. Spain Panic Attack Treatment Market
21. Eastern Europe Panic Attack Treatment Market
22. Russia Panic Attack Treatment Market
23. North America Panic Attack Treatment Market
24. USA Panic Attack Treatment Market
25. Canada Panic Attack Treatment Market
26. South America Panic Attack Treatment Market
27. Brazil Panic Attack Treatment Market
28. Middle East Panic Attack Treatment Market
29. Africa Panic Attack Treatment Market
30. Panic Attack Treatment Market Competitive Landscape And Company Profiles
31. Panic Attack Treatment Market Other Major And Innovative Companies
35. Panic Attack Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Panic Attack Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on panic attack treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for panic attack treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The panic attack treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Cognitive Behavioral Therapy (CBT); Medications; Other Treatment Types2) By Drug Class: Antidepressants; Anti-Anxiety Drugs; Calcitonin Gene-Related Peptide (CGRP) Antagonists; Other Drug Classes
3) By Route Of Administration: Oral; Intravenous; Intramuscular; Sublingual; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By Application: Hospitals; Mental Healthcare Centers; Other Applications
Subsegments:
1) By Cognitive Behavioral Therapy (CBT): Exposure Therapy; Dialectical Behavior Therapy (DBT); Acceptance And Commitment Therapy (ACT); Mindfulness-Based Cognitive Therapy (MBCT); Rational Emotive Behavior Therapy (REBT)2) By Medications: Beta Blockers; Buspirone; Anticonvulsants; Atypical Antipsychotics; Herbal And Natural Supplements
3) By Other Treatment Types: Telepsychiatry; Biofeedback And Neurofeedback; Virtual Reality Therapy; Mobile Health Applications; Support Groups And Counseling Services
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Sanofi S.A.
- AstraZeneca Plc
- Abbott Laboratories
- Novartis AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Sumitomo Dainippon Pharma
- Shionogi & Co. Ltd.
- Lundbeck A/S
- Recordati Rare Diseases
- Torrent Pharmaceuticals Ltd.
